Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

A Trial Investigating the Efficacy and Safety of Insulin Degludec/Insulin Aspart Once Daily Plus Insulin Aspart for the Remaining Meals Versus Insulin Detemir Once or Twice Daily Plus Meal Time Insulin Aspart in Children and Adolescents With Type 1 Diabetes Mellitus

ClinicalTrials.gov ID: NCT01835431

Public ClinicalTrials.gov record NCT01835431. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 10, 2026, 4:51 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Study identification

NCT ID
NCT01835431
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Novo Nordisk A/S
Industry
Enrollment
362 participants

Conditions and interventions

Interventions

  • insulin aspart Drug
  • insulin degludec/insulin aspart Drug
  • insulin detemir Drug

Drug

Eligibility (public fields only)

Age range
1 Year to 17 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 16, 2013
Primary completion
Nov 6, 2014
Completion
Nov 6, 2014
Last update posted
Jun 10, 2019

2013 – 2014

United States locations

U.S. sites
24
U.S. states
17
U.S. cities
22
Facility City State ZIP Site status
Novo Nordisk Investigational Site Phoenix Arizona 85053
Novo Nordisk Investigational Site Tucson Arizona 85724
Novo Nordisk Investigational Site Sacramento California 95816
Novo Nordisk Investigational Site Aurora Colorado 80045
Novo Nordisk Investigational Site Jacksonville Florida 32207
Novo Nordisk Investigational Site Maitland Florida 32751
Novo Nordisk Investigational Site Melbourne Florida 32901
Novo Nordisk Investigational Site Tallahassee Florida 32308
Novo Nordisk Investigational Site Tampa Florida 33612
Novo Nordisk Investigational Site Atlanta Georgia 30322
Novo Nordisk Investigational Site Atlanta Georgia 30339
Novo Nordisk Investigational Site Idaho Falls Idaho 83404-7596
Novo Nordisk Investigational Site Springfield Illinois 62703
Novo Nordisk Investigational Site Indianapolis Indiana 46202
Novo Nordisk Investigational Site Iowa City Iowa 52242
Novo Nordisk Investigational Site Lexington Kentucky 40503
Novo Nordisk Investigational Site Baltimore Maryland 21229
Novo Nordisk Investigational Site Worcester Massachusetts 01655
Novo Nordisk Investigational Site Kansas City Missouri 64111
Novo Nordisk Investigational Site Buffalo New York 14203
Novo Nordisk Investigational Site Tulsa Oklahoma 74135
Novo Nordisk Investigational Site Philadelphia Pennsylvania 19104
Novo Nordisk Investigational Site Philadelphia Pennsylvania 19107
Novo Nordisk Investigational Site Dallas Texas 75231

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 49 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01835431, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 10, 2019 · Synced May 10, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01835431 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →